Applicant, as named in the Orange Book

Emd Serono Inc

Next listed expiry: Tepmetko on 19 Mar 2030. 2 products with live protection, 1 without.

Products with listed protection

Drug	Ingredient	NDA	Earliest generic entry	Basis
Tepmetko tepotinib hydrochloride	tepotinib hydrochloride	214096	19 Mar 2030	patent
Mavenclad cladribine	cladribine	022561	10 Sep 2041	patent, carve-out possible

Products without listed protection (1)

Drug	Ingredient	NDA	Earliest generic entry	Basis
Cetrotide cetrorelix acetate	cetrorelix acetate	021197	open now	no listed protection